Logo

RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

Share this

RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

Shots:

  • The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204- currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease
  • Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the US specifically designed to treat OIC in adult patients with chronic non-cancer pain
  • RHB-204 has received FDA Fast Track- OD- and QIDP designations aimed at accelerating development and FDA review and extending the US market exclusivity to a potential total of 12 yrs. (to be granted at the time of FDA approval)

 ­ Ref: RedHill | Image: RedHill

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions